 CRISPR Therapeutics AG NASDAQ: CRSP, Syndax Pharmaceuticals, Inc. NASDAQ: SNDX and KalVista Pharmaceuticals, Inc. NASDAQ: KALV were among the early movers in the biopharma space Tuesday. CRISPR Rises On Gene Editing Therapy Pact With Vertex: CRISPR announced an amended collaboration agreement with Vertex Pharmaceuticals Incorporated NASDAQ: VRTX with respect to CTX001, an investigational CRISPRCas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia. 